Providence Health Plan Is Winding Down: What Your Clinic Should Do Before January 1
Providence Health Plan announced in May that it will exit most of its insurance business at the end of 2026, a decision that affects roughly 421,000 Oregonians across commercial, individual, marketplace, employer group, Medicare Advantage, and Medicaid lines. Members keep their current coverage through December 31, 2026, and Providence has said it will honor existing contracts through the end of the year.
For most patients, changing insurance is a paperwork headache. For patients on infusion and specialty therapy, it is a clinical risk. Every Providence patient on an infused medication will start 2027 under a new payer with new prior authorization requirements, a new formulary, new site-of-care rules, and a reset deductible. A missed therapy cycle is not just an inconvenience. For patients on immune globulin, biologics, or maintenance neurology therapies, it can mean clinical regression.
The good news: there is time to get ahead of this, but the window is now, not December.
What Your Patients Are Facing
Individual and marketplace members must choose a new plan when open enrollment begins November 1. Some may be auto mapped to a comparable plan, but nothing is guaranteed.
Employer group members transition as their employer’s contract expires, and Medicare Advantage members may move to a successor carrier.
Every patient will need a fresh prior authorization under their new plan, and January volume will slow every payer’s turnaround. The clinics that prepare in the fall will have patients infusing on schedule in January. The ones that wait will be in the queue with everyone else.
A Proactive Transition Plan for Your Clinic
Here is the playbook we are running with referring offices across the Portland metro area.
Identify your impacted patients now. Query your EMR for patients with Providence coverage on infusion or specialty therapy. For immune globulin, search by “immune globulin” or by brand: IVIG products include Gammagard, Gamunex-C, Privigen, Octagam, Panzyga, Bivigam, Asceniv, Gammaplex, Alyglo, Yimmugo, and Qivigy. SCIG products include Hizentra, Cuvitru, Xembify, Cutaquig, and HyQvia. No easy way to run that report? Keep a simple running log as Providence patients are seen by your providers.
Send them our way. Refer your Providence patients to us individually, or sign a Business Associate Agreement with us so we can work the full list directly on your clinic’s behalf.
Plan proactive patient outreach. We contact each patient to make sure they understand the deadline and encourage plan selection during open enrollment, so no one discovers the change when a claim denies in January.
Enroll in patient assistance before the gap. We enroll patients in manufacturer copay assistance programs in advance. Takeda, Grifols, CSL Behring, Kedrion, and Pfizer all offer programs for their immune globulin products. Most infusion pharmacies and hospital outpatient centers do not enroll patients proactively. With assistance in place, your patient stays on schedule while the new payer’s prior authorization is processed.
Build prior authorization packets in advance. We collate clinical documentation now, including diagnosis, trial history, labs, and notes, so the new payer’s PA submits on day one of coverage.
Run a benefits investigation on every new plan. Once a patient selects 2027 coverage, we verify formulary status, site-of-care rules, and medical versus pharmacy benefit routing before the calendar turns.
Ensure care continuity either way. If Vital Care of Portland cannot serve a patient because of a payer carve-out, we triage that patient to the plan’s preferred pharmacy rather than leave your office holding the referral.
Why Clinics Are Partnering with Vital Care of Portland on This
We are locally owned and ACHC accredited, with home infusion and a private infusion suite in Happy Valley. Most importantly for this transition, we bill through both the medical and the pharmacy benefit, which means we can follow your patient onto whatever plan they land on. Your referral coordinators get one point of contact through the entire transition, and your patients get a team that treats a January 2027 infusion date as a commitment, not a hope.
Start Now
If your practice has Providence patients on infusion therapy, let’s build the transition list together before open enrollment begins November 1.
Phone: 971-484-4940
Fax: 971-484-4950
Visit: vitalcareofportland.com
